GET DAILY SIGNALSAgios Pharmaceuticals (AGIO) Delivers Strong Q3 Revenue Growth With Regulatory Timeline Extended
Key Takeaways
- Agios reported total net revenue of $55.4 million for Q3 2026, more than four times the $12.9 million recorded in the same quarter last year.
- U.S. net product revenue reached $48.7 million, driven by the ongoing commercial launch of AQVESME in thalassemia.
- GAAP (Generally Accepted Accounting Principles) net loss per share was -$1.09, narrower than the consensus analyst estimate.
- The company's net loss narrowed to $65.0 million, down from $103.4 million a year earlier, while cash and marketable securities totaled $907.0 million.
- The FDA extended the PDUFA (Prescription Drug User Fee Act) goal date for mitapivat in sickle cell disease by three months, to February 1, 2027.
- For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for AGIO.
- You can also discover actionable ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Agios Pharmaceuticals, a Cambridge, Massachusetts-based commercial-stage biopharmaceutical company focused on rare hematologic diseases, is navigating a pivotal commercial transition. Its lead product, mitapivat (marketed as PYRUKYND and AQVESME), is now generating meaningful revenue growth, and this quarter marks the first time quarterly revenue exceeded the company’s entire 2025 total. In my view, the Q3 2026 report matters on two fronts: it shows whether the U.S. thalassemia launch is building a durable patient base, and it frames readiness for a much larger opportunity in sickle cell disease, where a regulatory decision remains pending. I also checked this using Tickeron’s AI Screener to see how AGIO compares to peers in the sector.
Reported Results
For the quarter ended September 30, 2026, Agios reported total net revenue of $55.4 million, compared with $12.9 million in the prior-year period. U.S. net product revenue was $48.7 million, up from $12.3 million a year earlier, while ex-U.S. revenue reached $6.6 million, driven by early access programs in Europe following the May 2026 European Union approval of PYRUKYND in thalassemia.
GAAP net loss per share came in at -$1.09, exceeding the consensus estimate of a wider loss. The company’s net loss was $65.0 million, an improvement from $103.4 million in Q3 2025. Operating expenses reflected a strategic shift: R&D expenses declined to $73.5 million from $86.8 million, while SG&A expenses rose to $56.5 million from $41.3 million, reflecting commercial investment behind the thalassemia launch and sickle cell preparations. From what I see, these trends point to disciplined spending alongside launch momentum.
Market Reaction and Investor Sentiment
Investor attention around this earnings event has been split between the strength of the commercial launch and the regulatory timeline for sickle cell disease. On October 9, 2026, the FDA asked for additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease, and subsequently classified Agios’s response as a major amendment, extending the review period by three months to February 1, 2027. Management emphasized that the benefit-risk profile remains unchanged and that no cases of liver injury similar to those seen in thalassemia have emerged in the sickle cell population. The stock’s reaction is likely to hinge on how investors weigh the strong revenue trajectory against the delayed but still anticipated regulatory catalyst.
Forward Outlook and Key Factors to Monitor
The central story for Agios going forward is the potential approval of mitapivat in sickle cell disease, its largest commercial opportunity. Management describes itself as “launch ready,” with commercial, medical, and patient support teams hired and trained, and manufacturing staged for day-one availability. The PDUFA goal date now stands at February 1, 2027, and labeling discussions with the FDA, including elements of a potential REMS, remain ongoing.
Beyond the regulatory decision, investors should watch the durability of the thalassemia franchise. Agios reported roughly 75% of patients remaining on AQVESME after six months of treatment, a retention figure that underpins the recurring revenue base of a chronic therapy. The company is also broadening demand through a direct-to-consumer campaign and expanding into the community setting.
On the pipeline front, Agios plans to initiate a Phase 3 program for AG-236 in polycythemia vera by year-end and a Phase 3 trial for cevidoplenib in immune thrombocytopenia in the first half of 2028. The company has also rightsized its operating model, targeting more than a 35% reduction in R&D headcount compared with 2025, with the goal of reaching non-GAAP profitability in 2028. Key near-term catalysts include presentations at the American Society of Hematology (ASH) Annual Meeting in December 2026. I’m watching this closely as the sickle cell catalyst approaches.
Using Tickeron Tools in My Research
In my regular analysis workflow, I turn to Tickeron’s AI Screener to quickly filter opportunities across sectors and compare fundamentals and technical signals side by side. It helps surface relevant peers and patterns without spending hours on manual screens, which keeps my focus on the data that matters most for names like AGIO.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AGIO's Stochastic Oscillator remains in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AGIO's RSI Oscillator exited the oversold zone, 15 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
Following a +4.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGIO advanced for three days, in 229 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AGIO as a result. In 80 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for AGIO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 37 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
AGIO moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AGIO crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
AGIO broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AGIO entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.711) is normal, around the industry mean (3.482). P/E Ratio (-4.195) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.685) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AGIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics
Industry Biotechnology
Advertisement